DUBLIN, Nov. 4, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/2wrs67/global_hospital) has announced the addition of the "Global Hospital Infection Therapeutics Market 2015-2019" report to their offering.
Covered in this report
The report covers the present scenario and growth prospects of the global hospital infection therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of drugs used in the treatment of various hospital-acquired infections such as bloodstream infections, Clostridium difficile infections, hospital-acquired pneumonia, surgical site infections, and urinary tract infections.
Patient assistance programs are expected to boost the growth of the market during the forecast period. Vendors provide co-pay assistance to individuals who purchase the indicated drugs for treating infections. Pfizer's drug Zyvox has a co-pay assistance program to provide financial assistance.
According to the report, surgeries for cardiac, renal, and gastrointestinal disorders and cesarean section for childbirth are commonly performed currently. Many individuals also choose esthetic enhancement surgeries such as maxillofacial and prosthetic surgeries. This leads to increased exposure to microbes in the hospital environment, thus leading to infections and other complications. Surgeries increase the length of stay in the hospital and individuals are at greater risk of contracting infections.
Further, the report states that generic drugs are similar in quality, dosage form, strength, and efficacy to branded drugs, but are available at lower prices. A branded drug can be manufactured as generic after losing its patent. Many of the anti-infective drugs such as ceftriaxone, ampicillin, ampicillin and sulbactam, and ertapenem, are available as generics in the market.
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Disease overview
PART 06: Pipeline analysis
PART 07: Market landscape
PART 08: Market segmentation by drug class
PART 09: Market segmentation by type of infections
PART 10: Geographical segmentation
PART 11: Market drivers
PART 12: Impact of drivers
PART 13: Market challenges
PART 14: Market trends
PART 15: Vendor landscape
PART 16: Key vendor analysis
For more information visit
Laura Wood, +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets